Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 June 2020
Cirrhosis in over 16s: assessment and management (NG50)Product type:GuidanceProgramme:NICE guidelineLast updated: 8 September 2023Published: 6 July 2016
Elafibranor for previously treated primary biliary cholangitis (TA1016)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 November 2024
Endoscopic ultrasound-guided biliary drainage for biliary obstruction (IPG761)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 19 April 2023
Everolimus for preventing organ rejection in liver transplantation (TA348)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2015
Extracorporeal albumin dialysis for acute liver failure (IPG316)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 September 2009
Extracorporeal bioartificial liver assist therapyStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Extracorporeal whole liver perfusion for acute liver failure (IPG690)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 31 March 2021
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (DG48)Product type:GuidanceProgramme:Diagnostics guidancePublished: 7 June 2023
LiMAx system for assessing the functional capacity of the liver (MIB168)Product type:AdviceProgramme:Medtech innovation briefingPublished: 16 January 2019
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)Product type:AdviceProgramme:Medtech innovation briefingPublished: 21 February 2023
LIVERFASt for diagnosing and staging liver injury and chronic liver disease, (MT783)Status:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
Living-donor liver transplantation (IPG535)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 25 November 2015
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 January 2020
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
MRI-based technologies for assessing non-alcoholic fatty liver disease (DG50)Product type:GuidanceProgramme:Diagnostics guidancePublished: 12 January 2023
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)Product type:GuidanceProgramme:NICE guidelinePublished: 6 July 2016
Non-alcoholic fatty liver disease (NAFLD): assessment and managementStatus:In developmentProgramme:NICE guidelineExpected publication date: TBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Obeticholic acid for treating primary biliary cholangitis (TA443)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 April 2017
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Odevixibat for treating progressive familial intrahepatic cholestasis (HST17)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 22 February 2022
OrganOx metra for liver transplant (MIB275)Product type:AdviceProgramme:Medtech innovation briefingPublished: 14 September 2021
OrganOx metra for liver transplant [ID5116]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis TS ID 11905Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2015
Seladelpar for previously treated primary biliary cholangitis ID6429Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 10 September 2025
Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (DG5)Product type:GuidanceProgramme:Diagnostics guidancePublished: 29 August 2012
Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis (IPG631)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 14 November 2018
The SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of the biliary system (MIB21)Product type:AdviceProgramme:Medtech innovation briefingPublished: 12 February 2015
Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (MTG27)Product type:GuidanceProgramme:Medical technologies guidanceLast updated: 17 January 2020Published: 23 September 2015